# GoodRx Holdings, Inc. (GDRX) FY2026 Q2 P&L / Income Statement

- Company: GoodRx Holdings, Inc. (GDRX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001809519-26-000152
- Page: https://plicit.ai/financials/gdrx/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/gdrx-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 200,411,000 US dollars
- **Cost of revenue (calculated)**: 20,999,000 US dollars
- **Gross profit (calculated)**: 179,412,000 US dollars
- **Operating expenses (calculated)**: 155,780,000 US dollars
- **Operating income**: 23,632,000 US dollars
- **Total other expense, net**: negative 8,166,000 US dollars
- **Income before income taxes**: 15,466,000 US dollars
- **Income tax expense**: 6,930,000 US dollars
- **Net income**: 8,536,000 US dollars
- **Prescription transactions revenue**: 106,390,000 US dollars
- **Subscription revenue**: 28,514,000 US dollars
- **Pharma Direct revenue**: 61,628,000 US dollars
- **Other revenue**: 3,879,000 US dollars
- **Cost of revenue, exclusive of depreciation and amortization presented separately below**: 20,999,000 US dollars
- **Product development and technology**: 26,711,000 US dollars
- **Sales and marketing**: 81,986,000 US dollars
- **General and administrative**: 24,814,000 US dollars
- **Depreciation and amortization**: 22,269,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.